Table 1.
List of studies used to form the oesophageal dataset. The total number of patients included is 505, from 21 studies. 3D-CRT: three-dimensional conformal radiotherapy, BED: biologically equivalent dose, cDmax: cumulative oesophageal maximal dose, EQD2: equivalent dose in 2 Gray fractions, Fr: fractions, IMPT: intensity modulated proton therapy, IMRT: intensity modulated radiotherapy, NR: not recorded, NSCLC: non-small cell lung cancer, RBE: relative biological effectiveness, Re-RT: re-irradiation, SABR: stereotactic ablative radiotherapy.
| Paper | n | Tumour type re-irradiated | Treatment span | Re-treatment Technique | Median cDmax | Interval (months, range) | Chemo % rate with re-RT | Any Grade 3–5 toxicity (%) | F/u post re-RT (months, range) |
|---|---|---|---|---|---|---|---|---|---|
| Poltinnikov [15] | 9 | NSCLC | 1999–2003 | 3D-CRT | 82.2 (66.8–96.3) | 13 (2–39) | 33.3 | 0 | 5.5 (2.5–30) (f/u to death) |
| Yamaguchi [16] | 12 | Oesophagus | 1996–2008 | 3D-CRT | 93.8 (87.0–98.9) | 8.5 (4–162) | 100 | 50 | 4 (1–108) |
| Kim [17] | 10 | Oesophagus | 2007–2011 | 3D-CRT | 98.7 (93.8–111.5) | 15.6 (4.8–36.4) | 30 | 30 | 4.9 (2.6–11.4) |
| Katano [18] | 4 | Oesophagus | 2011–2016 | 3D-CRT | 88.2 (71.9–97.9) | 17.4 (6.4–59.2) | 83.3 | 16.7 | 8.8 (1–30.4) |
| Hong [5] | 39 | Oesophagus | 2000–2014 | IMRT 56.4%, 3D-CRT 43.6% | 112 (80–140) | 16 (3–168) | 50 | 7.7 | 87 (2––206) |
| Zhou [19] | 55 | Oesophagus | 2003–2012 | IMRT or 3D-CRT | 115.2 (NR) | 12 (6–56) | NR | 20 | 20 (8–70) |
| Chen [20] | 36 | Oesophagus | 1996–2005 | IMRT | 99.2 (99.2–107.7) | 14.6 (4.5–165) | 100 | 52.8 | 62 (8–192) (whole group including surgery patients) |
| Kennedy [21] | 21 | NSCLC | 2008–2017 | SABR | 18.7 (4.9–37.2) | 23 (7–52) | 0 | 0 | 24 (3–60) |
| Schlampp [22] | 62 | NSCLC | 2010–2015 | IMRT | 89.9 (NR) | 14 (3–103) | 3.2 | 4.8 | 8.2 (0–27) |
| Schroder [23] | 30 | NSCLC | 2011–2017 | SABR | 81.0 (70.2–103.8) | 14 (2–184) | 0 | 0 | 13 (1–45) |
| Meijneke [24] | 8 | NSCLC | 2005–2012 | 90% SABR, 10% Conventional | 85.2 (70.5–123.2) | 17 (2–33) | 0 | 0 | 12 (2–52) |
| Owen [25] | 18 | NSCLC | 2006–2012 | SABR | 62.5 (38.9–78.4) | 18.4 (1.5–112.8) | 0 | 0 | 21.2 (3.4–50.2) |
| Kilburn [26] | 33 | NSCLC | 2001–2012 | SABR in 91% | 69 (11–129) | 18 (6–61) | 0 | 3 | 17 (NR) |
| Sumita [27] | 21 | NSCLC | 2007–2014 | Conventional 90%, Proton 10% | 73 (NR) | 26.8 (11.4–92.3) | 5 | 0 | 22.1 (2.3–56.4) |
| Binkley [28] | 38 | NSCLC | 2008–2014 | SABR 73.7%, Conventional 26.3% | 44.1 (3.7–220.6) | 16 (1–71) | 23.7 | 2.6 | 17 (3–57) |
| Maranzano [29] | 18 | NSCLC or mets | 2003–2013 | SABR | 45 (4–138) | 18 (6–90) | 0 | 0 | 57 (6–132) |
| Ho [30] | 27 | NSCLC | 2011–2016 | Proton (IMPT) | 84.8 (57.1–121) | 29.5 (0.1–212.3) | 48 | 0 | 11.2 (2.4–48.5) |
| Hong [31] | 31 | NSCLC | 2005–2016 | IMRT 67.7%, SABR 32.3% | 74.4 (NR) | 15.1 (4.4–56.3) | 9.7 | 0 | 17.4 (4.8–76.8) |
| Ogawa [32] | 31 | NSCLC or mets | 2004–2017 | SABR | 19.4 (0.8–146.8 | NR | 0 | 0 | 26 (5.5–111) |
| Griffioen [33] | 1 | NSCLC | 2004–2013 | Conventional | 120 | 62 | NR | 100 | 6 |
| McAvoy [34] | 1 | NSCLC | 2006–2011 | Protons | 135.7 | 36 | NR | 100 | 29 |